Support our Foundation of Myology project
ARGX-113-2007 ALKIVIA
A phase 2/3, randomised, double-blind, placebo-controlled study evaluating the efficacy and safety of efgartigimod PH20 SC in patients with active idiopathic inflammatory myopathy.
Support our Foundation of Myology project
A phase 2/3, randomised, double-blind, placebo-controlled study evaluating the efficacy and safety of efgartigimod PH20 SC in patients with active idiopathic inflammatory myopathy.